MAIA Biotechnology, Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-05.
MAIA Biotechnology, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 5, 2026. The filing reports $1.51M sold. Its industry group is Biotechnology. It names Vlad Vitoc (Chief Executive Officer, President and Chairman of the Board of Directors), Jeffrey Himmelreich (Head of Finance), Sergei Gryaznov (Chief Scientific Officer) (SEC Form D, January 5, 2026).
Sell to companies like MAIA Biotechnology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-05 · the record
Pitching, partnering or investing alongside them? See who really runs and owns MAIA Biotechnology, Inc.
Free to see. No signup.
More on the people and the money behind MAIA Biotechnology, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when MAIA Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when MAIA Biotechnology, Inc. raises, hires or launches. No email unless you switch it on.
Watch MAIA Biotechnology, Inc. →Get the full cited report on MAIA Biotechnology, Inc.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on MAIA Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for MAIA Biotechnology, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on MAIA Biotechnology, Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $1.51M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Vlad Vitoc is named as Chief Executive Officer, President and Chairman of the Board of Directors on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
On the filing as: Executive Officer, Director.
Jeffrey Himmelreich is named as Head of Finance on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
On the filing as: Executive Officer.
Sergei Gryaznov is named as Chief Scientific Officer on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
Jean-Manasse Theagene is named as Director on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
Steven Chaouki is named as Director on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
Stan Smith is named as Director on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
Ramiro Guerrero is named as Director on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
Louie Yee is named as Director on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
Cristian Luput is named as Director on the Form D that MAIA Biotechnology, Inc. filed with the SEC on 5 January 2026, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2026-01-05 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on MAIA Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MAIA Biotechnology, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist MAIA Biotechnology, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind MAIA Biotechnology, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for MAIA Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Chicago
https://mentionfox.com/funding/maia-biotechnology-inc-form-d-26000001